Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
9.49
+0.16 (1.71%)
Feb 6, 2026, 4:00 PM EST - Market closed
Valneva SE Employees
Valneva SE had 700 employees as of June 30, 2025.
Employees
700
Change
n/a
Growth
n/a
Revenue / Employee
$301,557
Profits / Employee
-$171,234
Market Cap
826.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 700 | - | - |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Maravai LifeSciences Holdings | 550 |
| Arvinas | 430 |
| Xencor | 250 |
| Geron | 229 |
| Omeros | 202 |
| Janux Therapeutics | 109 |
| Annexon | 99 |
| ArriVent BioPharma | 52 |
VALN News
- 1 day ago - VALNEVA Declaration of shares and voting rights: January 31, 2026 - GlobeNewsWire
- 4 days ago - Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 19 days ago - Valneva withdraws application for standard US approval of its chikungunya shot - Reuters
- 19 days ago - Valneva Provides Update on Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 4 weeks ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Valneva SE - Declaration of voting rights - December 2025 - GlobeNewsWire
- 5 weeks ago - Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement - GlobeNewsWire
- 2 months ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire